Episode Details
Back to Episodes
JNJ Balances Growth, Patent Transitions, and Legal Overhangs
Description
Arthur Wong and Andy Wang break down Johnson & Johnson’s (JNJ) strong quarterly results and raised full‑year guidance despite a muted stock reaction. They explain how the company is navigating the Stelara patent cliff by shifting patients to next‑generation therapies, with oncology emerging as a key growth driver. The discussion also weighs ongoing talc litigation risk against JNJ’s strong balance sheet and ability to continue investing heavily in R&D.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6D
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch
Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – https://twitter.com/schwabnetwork
Follow us on Facebook – https://www.facebook.com/schwabnetwork
Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/
About Schwab Network - https://schwabnetwork.com/about